Hot Topics in Indolent Lymphoma
In this segment, “Indolent B-cell Lymphomas”, Loretta Nastoupil, MD and Peter Martin, MD discuss recent advances and challenges in the treatment of patients with indolent B-cell lymphoma.
Recent approvals and emerging therapies are improving outcomes for patients with relapsed and refractory disease while creating questions regarding selection and sequencing of therapy. CAR T-cell therapy has resulted in improved survival and tumor responses in heavily pretreated patients with follicular lymphoma compared to other available therapies. Bispecific antibodies have shown promising initial results, including activity in patients failing CAR T-cell therapy, and have the potential to expand community-based administration and increase access to patients well beyond the academic treatment setting. Optimal clinical use of cellular therapies in indolent B-cell lymphomas remains to be established.